The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System (SPHERE Per-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05120193
Recruitment Status : Completed
First Posted : November 15, 2021
Last Update Posted : April 10, 2024
Sponsor:
Information provided by (Responsible Party):
Affera, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospective, multicenter, randomized clinical evaluation of the Sphere-9 Mapping and Ablation Catheter with the Affera Mapping and Ablation System. Subjects will be randomly assigned 1:1 to receive treatment with either the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System (investigational device) or the THERMOCOOL SMARTTOUCH® SF radiofrequency ablation catheter (control device).

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Device: Mapping and Ablation Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 477 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description: Subjects will be blinded to treatment assignment
Primary Purpose: Treatment
Official Title: Treatment of Persistent Atrial Fibrillation With the Sphere-9 Mapping and Ablation Catheter and the Affera Mapping and Ablation System
Actual Study Start Date : December 14, 2021
Actual Primary Completion Date : January 10, 2024
Actual Study Completion Date : January 10, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Sphere-9 Catheter
Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
 Device: Mapping and Ablation
Minimally invasive catheter mapping and ablation procedure
Active Comparator: THERMOCOOL SMARTTOUCH SF
THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System
 Device: Mapping and Ablation
Minimally invasive catheter mapping and ablation procedure


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent of subjects with a primary adverse event [ Time Frame: 180 Days ]

    The primary safety endpoint is the incidence of the following device- or procedure-related serious adverse events (SAEs) following the index ablation procedure:

    Within 7 days:

    • Death
    • Myocardial infarction
    • Phrenic nerve paralysis
    • Transient ischemic attack (TIA)
    • Stroke/cerebrovascular accident (CVA)
    • Thromboembolism
    • Major vascular access complications / bleeding
    • Heart block
    • Gastroparesis
    • Severe pericarditis
    • Hospitalization due to cardiovascular or pulmonary AE

    Within 30 days:

    • Cardiac tamponade / perforation

    Within 90 days:

    • Atrio-esophageal fistula

    Within 180 days:

    • Pulmonary vein stenosis


  2. Percent of subjects free from primary effectiveness failure [ Time Frame: 12 months ]

    The primary effectiveness endpoint is freedom from documented recurrence of atrial tachyarrhythmias excluding the 90-day blanking period. The following are also considered primary effectiveness endpoint failures:

    • Acute procedural failure
    • Non-study catheter failure
    • Repeat ablation/surgery failure
    • AAD failure
    • Cardioversion failure


Secondary Outcome Measures :
  1. Energy application time [ Time Frame: Day 0 ]
    Total energy application time during the index ablation procedure

  2. Treatment time [ Time Frame: Day 0 ]
    Time from start to end of energy delivery

  3. Procedure time [ Time Frame: Day 0 ]
    Time from start to end of venous access


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Symptomatic PerAF documented by (1) a physician's note indicating symptoms consistent with AF sustained longer than 7 days but less than 12 months; AND either (2a) a 24-hour Holter documenting continuous AF within the past year OR (2b) two electrocardiograms (from any form of rhythm monitoring, including consumer devices) taken at least 7 days apart within the past year, each showing continuous AF.
  2. Failure or intolerance of at least one Class I or III anti-arrhythmic drug (AAD).
  3. Suitable candidate for catheter ablation.
  4. Adults aged 18 - 80 years.
  5. Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.
  6. Willing and able to provide informed consent.

Exclusion Criteria:

  1. Continuous AF lasting for 12 months or longer.
  2. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or other reversible or non-cardiac cause.
  3. Previous left atrial ablation or surgical procedure (including septal closure or left atrial appendage closure).
  4. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
  5. Any carotid stenting or endarterectomy.
  6. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention within the 90 days prior to the initial procedure.
  7. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the initial procedure.
  8. Awaiting cardiac transplantation or other cardiac surgery within the 12 months following the initial ablation procedure.
  9. Presence of a permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator (with or without biventricular pacing function).
  10. Documented thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the initial ablation procedure.
  11. Documented left atrial thrombus on imaging.
  12. History of blood clotting or bleeding abnormalities.
  13. Any condition contraindicating chronic anticoagulation.
  14. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial procedure.
  15. Body mass index >40 kg/m2.
  16. Left atrial diameter >55 mm (anterioposterior).
  17. Diagnosed atrial myxoma.
  18. Left ventricular ejection fraction (EF) < 35%.
  19. Uncontrolled heart failure or NYHA Class III or IV heart failure.
  20. Rheumatic heart disease.
  21. Hypertrophic cardiomyopathy.
  22. Unstable angina.
  23. Moderate to severe mitral valve stenosis.
  24. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
  25. Primary pulmonary hypertension.
  26. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.
  27. Renal failure requiring dialysis.
  28. History of severe Gastroesophageal Reflux Disease (GERD) requiring surgical and/or mechanical intervention.
  29. Acute illness, active systemic infection, or sepsis.
  30. Contraindication to both computed tomography and magnetic resonance angiography.
  31. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical study results.
  32. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.
  33. Current or anticipated participation in any other clinical study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
  34. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.
  35. Known drug or alcohol dependency.
  36. Life expectancy less than 12 months.
  37. Vulnerable subject (such as a prisoner or handicapped or mentally disabled person).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05120193


Locations
Show Show 23 study locations
Sponsors and Collaborators
Affera, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Affera, Inc.
ClinicalTrials.gov Identifier: NCT05120193    
Other Study ID Numbers: CP-00009
First Posted: November 15, 2021    Key Record Dates
Last Update Posted: April 10, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes